In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, discusses the impact of Medicare Part D drug price negotiations on manufacturers’ go-to-market strategies and decisions, as well as We talk about the industry’s response to the dialogue. Pricing transparency.
Pricing environment influencing commercial considerations
You Might Also Like
Leave a Comment